The director of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Declan Doogan sold 37,740 shares of the company in a transaction dated Tuesday, November 16. The stock was sold at an average price of $ 116.65, for a total trade of $ 4,402,371.00. The transaction was disclosed in a file with the SEC, which is available through this link.
Biohaven Pharmaceutical stock traded down $ 3.01 in the midday session Wednesday, reaching $ 116.35. 477,157 shares of the company traded hands, compared to its average volume of 585,428. The company has a market cap of $ 7.62 billion, a price / earnings ratio of -8.50 and a beta of 0 , 95. The company has a 50-day moving average of $ 135.50 and a two-hundred-day moving average of $ 115.46. Biohaven Pharmaceutical Holding Company Ltd. has a 12-month low of $ 62.57 and a 12-month high of $ 151.51.
Biohaven Pharmaceutical (NYSE: BHVN) last reported its results on Monday, November 8. The company reported ($ 2.63) EPS for the quarter, missing Zacks’ consensus estimate of ($ 2.40) of ($ 0.23). The company posted revenue of $ 135.74 million for the quarter, compared to analysts’ estimates of $ 128.40 million. During the same period of the previous year, the company posted ($ 3.27) earnings per share. The company’s revenue increased 668.5% compared to the same quarter last year. Analysts on the seller’s side predict that Biohaven Pharmaceutical Holding Company Ltd. will post earnings per share of -12.08 for the current fiscal year.
Several research analysts recently published reports on BHVN shares. The Goldman Sachs group raised its price target for Biohaven Pharmaceutical shares from $ 151.00 to $ 170.00 and assigned the stock a “buy” rating in a research note on Wednesday, October 6. UBS Group downgraded Biohaven Pharmaceutical’s stock rating from a “buy” rating to a “neutral” rating and increased its target price from $ 108.00 to $ 109.00 in a research note on Tuesday August 10. Morgan Stanley raised its price target for Biohaven Pharmaceutical shares from $ 107.00 to $ 145.00 and gave the stock an “equal weight” rating in a Tuesday October 19 research note. HC Wainwright reiterated a “buy” note and issued a price target of $ 160.00 (up from $ 135 previously) on shares of Biohaven Pharmaceutical in a research note on Wednesday, October 6. Finally, Cantor Fitzgerald raised his price target for Biohaven Pharmaceutical shares from $ 165.00 to $ 177.00 and assigned the stock an “overweight” rating in a Wednesday, November 10 research note. Three research analysts rated the stock with a conservation rating and nine issued a buy rating for the company’s stock. According to MarketBeat data, Biohaven Pharmaceutical currently has an average “Buy” rating and a consensus price target of $ 141.82.
Hedge funds have recently changed their positions in the company. Thrivent Financial for Lutherans increased its stake in shares of Biohaven Pharmaceutical by 185.1% in the second quarter. Thrivent Financial for Lutherans now owns 1,416,890 shares of the company valued at $ 137,552,000 after purchasing an additional 919,951 shares during the last quarter. BlackRock Inc. increased its stake in Biohaven Pharmaceutical shares by 24.0% in the second quarter. BlackRock Inc. now owns 4,691,578 shares of the company valued at $ 455,460,000 after purchasing an additional 908,024 shares during the last quarter. Macquarie Group Ltd. increased its stake in Biohaven Pharmaceutical shares by 27,669.6% in the third quarter. Macquarie Group Ltd. now owns 520,124 shares of the company valued at $ 72,251,000 after purchasing an additional 518,251 shares during the last quarter. Polar Capital Holdings Plc increased its stake in shares of Biohaven Pharmaceutical by 40.3% in the third quarter. Polar Capital Holdings Plc now owns 1,256,472 shares of the company valued at $ 174,537,000 after purchasing an additional 360,740 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Biohaven Pharmaceutical shares by 26.1% in the second quarter. Wells Fargo & Company MN now owns 1,431,187 shares of the company valued at $ 138,939,000 after purchasing an additional 295,977 shares during the last quarter. 91.05% of the shares are held by institutional investors and hedge funds.
Profile of the pharmaceutical company Biohaven
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It focuses on a pipeline of product candidates that represent mechanistic platforms, peptide receptor antagonists linked to the calcitonin gene, and glutamate modulators.
Further reading: What is net asset value (NAV)?
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Biohaven Pharmaceutical was not on the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here